Key result
Rivaroxaban attenuates systemic IL-6, while dabigatran reduces lung neutrophil infiltration in sickle mice.
Answers are grounded in this paper and cite their sources.
Activation of coagulation and vascular inflammation are prominent features of sickle cell disease (SCD). Previously, we have shown that inhibition of tissue factor (TF) attenuates activation of coagulation and vascular inflammation in mouse models of SCD. In this study, we examined the mechanism by which coagulation proteases enhance vascular inflammation in sickle BERK mice. To specifically investigate the contribution of FXa and thrombin, mice were fed chow containing either rivaroxaban or dabigatran, respectively. In addition, we used bone marrow transplantation to generate sickle mice deficient in either protease activated receptor-1 (PAR-1) or protease activated receptor-2 (PAR-2) on nonhematopoietic cells. FXa inhibition and PAR-2 deficiency in nonhematopoietic cells attenuated systemic inflammation, measured by plasma levels of interleukin-6 (IL-6). In contrast, neither thrombin inhibition nor PAR-1 deficiency in nonhematopoietic cells affected plasma levels of IL-6 in sickle mice. However, thrombin did contribute to neutrophil infiltration in the lung, independently of PAR-1 expressed by nonhematopoietic cells. Furthermore, the TF-dependent increase in plasma levels of soluble vascular cell adhesion molecule-1 in sickle mice was not mediated by FXa or thrombin. Our data indicate that TF, FXa, and thrombin differentially contribute to vascular inflammation in a mouse model of SCD.
No takes yet. Share an insight, caveat, or question.
Sparkenbaugh et al. (2014) studied Sickle cell disease (mouse model). Rivaroxaban (FXa inhibition) or dabigatran (thrombin inhibition); PAR-1 or PAR-2 deficiency vs. Control sickle mice was evaluated on Vascular and systemic inflammation (plasma IL-6, lung neutrophil infiltration, soluble VCAM-1). FXa inhibition (rivaroxaban) and nonhematopoietic PAR-2 deficiency attenuated plasma IL-6 levels in sickle BERK mice, whereas thrombin inhibition (dabigatran) reduced lung neutrophil infiltration.
Synapse has enriched 10 related papers. Consider them for comparative context: